Drug, bio-affecting and body treating compositions inventions 10/07

20070249519 - Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease: The present invention is directed to novel compositions and their application as pharmaceuticals for the treatment of disease. Methods of upregulation of GLUT4 via activation of peroxisome proliferator activated receptor delta activity in the adipose tissue of a human or animal subject are also provided, for the treatment of conditions... Agent: Global Patent Group Attn: Ms Lavern Hall

20070249536 - Three-component polyanhydride copolymers and a method of forming the same: A three-component polyanhydride copolymer having tunable erosion properties includes a sebacic acid anhydride precursor, a 1,3-bis(carboxyphenoxy) propane anhydride precursor, and a poly(ethylene glycol) anhydride precursor. The erosion rate of the copolymer increases with an increasing amount of the poly(ethylene glycol) precursor. A method for forming the three-component polyanhydride copolymer includes... Agent: Julia Church Dierker Dierker & Associates, P.C.

20070249543 - Dissolution of arterial cholesterol plaques by phytochemical emulsifiers: As a result of this phyto-pharmacological direct action upon the atherosclerotic plaque by the phytocompound resulting in the dissolution of the cholesterol aggregates of the plaque, the plaque is no longer vulnerable to rupture and arterial flow is restituted to physiological values present prior to plaque formation. This effect on... Agent: Filiberto Zadini

20070249556 - Method of treating inflammation: This invention provides methods of preventing and/or treating diseases or conditions associated with inflammation in a mammal, particularly a human. The method comprises administering to a mammal in need thereof an effective amount of a compound of Formula I, IA, or IB, wherein said amount is effective to inhibit inflammation.... Agent: Howery LLP

20070249561 - pharmacological method for treatment of neuropathic pain: Disclosed are methods and compositions useful for treatment of neuropathic pain. In particular, the present invention provides methods of activating gamma-subtype peroxisome proliferator-activated receptors (PPARγ) to inhibit, relieve, or treat neuropathic pain.... Agent: Adams And Reese LLP

20070249518 - Compositions and methods for treating mental disorders: The present invention relates, generally, to methods and compositions for detecting or treating mental disorders, such as schizophrenia or bipolar disorder. The present invention more particularly discloses the identification of human genes that can be used for the diagnosis, prevention and treatment of schizophrenia, bipolar disorder and related disorders, as... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070249522 - Injectable formulations containing succinate: The invention is directed to formulations of a pharmaceutically active agent for in vivo use. The formulations to which the invention is directed are designed to minimize the pain associated with components in injectable formulations, other than the pharmaceutically active agent. The invention is particularly directed to buffers that provide... Agent: Novartis Vaccines And Diagnostics Inc.

20070249520 - Stable emulsion formulations: The present invention relates to injectable formulations of irritant agents, such as calcimimetics, that are pharmaceutically stable and demonstrate a reduced incidence of irritation, pain, phlebitis, precipitation and hemolysis upon injection.... Agent: Marshall, Gerstein & Borun LLP

20070249521 - Synthetic antimicrobial polypeptides: The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.... Agent: Novozymes North America, Inc.

20070249524 - High affinity ligands bind to clostridium difficile toxin a: Glycans are identified which have high affinity for C. difficile toxin A. They share one of two saccharide backbones and may have additional side chains. The backbones are galactose-β1-3 N-acetyl-D-glucosamine-β-1-3-galactose-β-1-4-N-acetyl-D-glucosamine and galactose-α-1-3-galactose-β-1-4-N-acetyl-D-glucosamine. The ligands may be used therapeutically, prophylactically, and diagnostically.... Agent: Banner & Witcoff, Ltd.

20070249523 - Neurotherapeutic composition and method therefor: Neurotherapeutically effective pharmaceutical compositions are described that include carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are β-lactam compounds, particularly penam and cephem β-lactam antibiotics and non-antibiotic derivatives thereof.... Agent: Barnes & Thornburg LLP

20070249525 - Use of erythropoietin in the treatment of rheumatoid arthritis: A novel use of the known protein erythropoietin (EPO), and/or a derivative, and/or a fragment thereof, is disclosed. EPO is used as a pharmaceutical for the treatment of chronic inflammations. A particularly beneficial result is seen in patients suffering from rheumatoid arthritis (RA). Significant effects are seen in clinical variables... Agent: Trask Britt

20070249527 - Cyclosporin derivatives for the treatment of immune disorders: where Q, W, X, Y, and Z are defined herein. In a second embodiment, the present invention relates to pharmaceutical compositions comprising pro-drugs or pharmaceutically acceptable salts of the compounds of the present invention and the use thereof for treating autoimmune diseases or for the prevention of organ transplantation rejection... Agent: Elmore Patent Law Group, PC

20070249526 - Process for the preparation of cyclic peptides: The present invention relates to a process for the preparation of cyclic peptides, in particular the preparation of Ac-Phe[Orn-Pro-D-Cha-Trp-Arg] known as 3D53 or PMX53 which is a macrocyclic peptidomimetic of the human plasma protein C5a and displays excellent anti-inflammatory activity.... Agent: Haynes And Boone, LLP

20070249538 - soluble tnf receptors and their use in treatment of disease: The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular,... Agent: Thelen Reid Brown Raysman & Steiner LLP

20070249537 - Absorption enhancing agents: Disclosed are new compounds that increase the absorption of pharmaceutical agents across mucous membranes. These absorption enhancers allow higher bioavailability of administered drugs. The enhancers advantageously have low or no cytotoxicity.... Agent: Foley And Lardner LLP Suite 500

20070249530 - Bcma polypeptides and uses thereof: The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention... Agent: Merchant & Gould PC

20070249529 - Compositions comprising polypeptides: The present invention relates to compositions comprising polypeptides, especially polypeptides capable of specifically binding predetermined antigens. The polypeptide in the composition comprises at least two antigen binding sites. These at least two antigen binding sites are located on a single polypeptide chain. One of the at least two antigen binding... Agent: Fulbright & Jaworski L.L.P.

20070249528 - Histamine binding compounds for treatment method for disease conditions mediated by neutrophils: The invention relates to a novel method for the treatment of disease conditions that are mediated by neutrophil cells. The method involves the administration to a patient suffering from such a condition, a histamine binding compound in a therapeutically-effective amount.... Agent: Klauber & Jackson

20070249533 - Il-17a and il-17f antagonists and methods of using the same: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are... Agent: Zymogenetics, Inc. Intellectual Property Department

20070249531 - Method for the detection of autoantibodies against specific peptides and its use in diagnosis and treatment of pregnancy-loss or infertility: A method of assessing the titre of fertility-relevant autoantibodies of a mammalian female, wherein said method comprises: the presentation of a defined single molecule capable of binding to the idiotype of the fertility-relevant autoantibody, and determining the amount of autoantibody being bound by said molecule from a sample of a... Agent: Venable LLP

20070249535 - Methods for treating bone tumors: The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070249532 - Modified growth hormones: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.... Agent: Fish & Richardson, PC

20070249534 - Novel medicament for treating neurodegenerative diseases: A medicament for treating neurodegenerative diseases, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from the C-terminal of selenoprotein P. An excellent medicament for treating neurodegenerative diseases, especially suitable for treating neurodegenerative diseases with ataxia as a principal symptom is... Agent: Birch Stewart Kolasch & Birch

20070249539 - Use of vegf and homologues to treat neuron disorders: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion... Agent: Amster, Rothstein & Ebenstein LLP

20070249540 - Methods for inhibiting proteasome and heat shock protein 90: The present application provides methods for the inhibition of proteasome and heat shock protein Hsp90.... Agent: Adonia Papathanassiu

20070249541 - Combined use of enzyme inhibitors and of pharmaceutical compositions thereof: Provided are combinations of inhibitors of dipeptidyl peptidase IV (DP IV) and of enzymes having the same substrate specificity (DP IV-analogous enzymatic activity) and inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) and of enzymes having the same substrate specificity (APN-analogous enzymatic activity) and use of the same to obtain a... Agent: Hodgson Russ LLP The Guaranty Building

20070249542 - Treatment and prophylaxis of sepsis and septic shock: A method and composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids.... Agent: Powell Goldstein LLP

20070249544 - Crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments: The invention relates to a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070249545 - Dihydrofolate reductase inhibition by epigallocatechin gallate compounds: This invention relates to the identification, production and use of Dihydrofolate Reductase (DHFR) inhibitors based on the green tea catechin Epigallocatechin Gallate (EGCG). These inhibitors are, for example, useful in therapy, in particular for the treatment of cancer, infection and inflammatory conditions.... Agent: Klarquist Sparkman, LLP

20070249546 - Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them: The invention relates generally to concentrates and aqueous solutions for topical application comprising antifungal additives or agents as well as to preparation and use of such concentrates and solutions. More specifically, the invention relates to preparation and use of solutions that come in contact with the eye lids and/or eyes,... Agent: Darby & Darby P.C.

20070249547 - Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines: A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and... Agent: Connolly Bove Lodge & Hutz LLP

20070249548 - Nucleoside analog or salts of the same: It is an object to provide a nucleoside analog that can produce an oligonucleotide analog in which the two properties of chemical and biological stability, and the ability to form double strands, are excellent, and an oligonucleotide analog that includes that nucleoside analog. This is achieved by a nucleoside analog... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070249551 - Compositions and methods for non-parenteral delivery of oligonucleotides: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070249552 - Compositions and methods for sirna inhibition of primate polyomavirus genes: RNA interference using small interfering RNAs which are specific for mRNA produced from the JCV agnoprotein and large T antigen genes inhibits expression of these and other primate polyomavirus genes. Primate polyomavirus infection, and diseases which are associated with primate polyomavirus infection, can be treated by administering the small interfering... Agent: Nath & Associates

20070249549 - Compounds and methods for rna interference of the p65 subunit of nf-kappa-b: This invention relates to compounds, compositions, and methods useful for modulating the expression and activity of NF-kappa-B by RNA interference (RNAi) using small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA) and double-stranded RNA (dsRNA). Furthermore the invention provides methods for preventing, treating or... Agent: Morrison & Foerster LLP

20070249554 - Methods for therapy of neurodegenerative disease of the brain: A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified... Agent: Stacy L. Taylor, Esq. Dla Piper US LLP

20070249550 - Modulation of immune response and inflammation by targeting hypoxia inducible factors: Methods for modulating inflammation by administering HIF-1α inhibitors or compounds affecting HIF-1α expression and/or transcriptional activities are disclosed. HIF-1α affecting compounds include compounds that directly inhibit HIF-1α and/or interfere into expression of other proteins and regulation of biochemical pathways that target HIF-1α for degradation in vivo. Also disclosed are methods... Agent: Elmore Patent Law Group, PC

20070249553 - Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter: Nucleic acids encoding Campylobacter proteins, in particular antigenic proteins such as a flagellin, or encoding a variant thereof, or a fragment of either of these, are capable of protecting poultry such as chickens, against colonisation by Campylobacter, and so may be used in veterinary therapy or prophylaxis. This has an... Agent: The Mccallum Law Firm, P. C.

20070249555 - Use of atp analogues for treatment of cardiovascular diseases: Use of N-alkyl-2-substituted ATP analogues, pharmaceutically acceptable salts, metabolites or prodrugs thereof, for the preparation of a medicament intended to be used in the prevention and/or the treatment of cardiovascular diseases, pharmaceutical compositions comprising such compounds and a method for screening such compounds.... Agent: Oliff & Berridge, PLC

20070249557 - Compositions and methods for viscosupplementation: The invention provides viscosupplementation compositions that include hyaluronic acid, or a polymer thereof and a tribonectin, or an analog, derivative, or fragment thereof. Such compositions are useful for the lubrication and chondroprotection of mammalian joints.... Agent: Clark & Elbing LLP

20070249558 - System and method for promoting coronary angiogenesis: Systems and methods for promoting coronary angiogenesis employ a combination of mechanical, metabolic and biochemical stimuli.... Agent: Medtronic, Inc.

20070249559 - Hydrating composition: The present invention relates to methods and compositions for enhancing the ability of the body to absorb ingested water and retain water in the tissues. Compositions and methods of the invention may be used for increasing athletic performance in the heat, as well as for preventing and treating dehydration. The... Agent: Dann, Dorfman, Herrell & Skillman

20070249560 - Hydrolysis resistant organomodified silyated surfactants: Organomodified silylated surfactant compositions that exhibit resistance to hydrolysis over a wide pH range... Agent: Momentive Performance Materials Inc.IPLegal

20070249562 - Treatment of atrial fibrillation: The invention includes a method of treating atrial fibrillation in a mammal that includes administering a therapeutically effective amount of at least one therapeutic compound Compounds suitable for use in the methods of the invention include pyridoxal-5′-phosphate, pyridoxic acid, pyridoxamine, pyridoxal, 3-acylated pyridoxal analogues, pharmaceutically acceptable acid addition salts thereof,... Agent: Merchant & Gould PC

20070249563 - Process for preparing fosphenytoin: Processes for preparing fosphenytoin.... Agent: Dr. Reddy's Laboratories, Inc.

20070249564 - Novel phosphorus-containing prodrugs: o

20070249565 - Class of gamma delta t cells activators and use thereof:

20070249566 - Compositions and methods useful for treatment of respiratory illness: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070249568 - 17,20(e)-dehydro vitamin d analogs and their uses: This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25 -dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20070249567 - 2-methylene-19,26,27-trinor-(20s)-1alpha-hydroxyvitamin d3 and its uses: This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20070249569 - 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses: This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20070249570 - Homogeneously formulating microdosed active principles: A microdose of at least one active principle is essentially homogeneously formulated within at least one excipient therefor, via the following steps: 1. weighing the at least one active principle in a receptacle lined with a petroleum jelly; 2. encapsulating the active principle with additional petroleum jelly; 3. introducing the... Agent: Buchanan, Ingersoll & Rooney PC

20070249571 - Novel conjugate compounds and dermatological compositions thereof: The invention relates to novel cosmetic and dermatological compositions, comprising conjugate compounds, including a dicarboxylic acid moiety, which is covalently linked through covalent bonds to a biologically active alcohol, selected from the group of steroidal hormones, steroidal anti-inflammatory agents, vitamin E and vitamin D.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070249573 - 17alpha-substituted 4-(3-oxoestra-4,9-dien-11beta-yl)-benzoic acid, its derivatives and process for its production: This invention relates to 17α-substituted 4-(3-oxoestra-4,9-dien-11β-yl)-benzoic acids and derivatives thereof, a process for the production of these compounds, the use of the compounds for the production of pharmaceutical agents as well as pharmaceutical compositions that contain these compounds.... Agent: Millen, White, Zelano & Branigan, P.C.

20070249572 - Systems and methods for the delivery of corticosteroids: The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic... Agent: Wilson Sonsini Goodrich & Rosati

20070249574 - Stanol composition and the use thereof: A stanol composition containing in addition to sitostanol as the main component, also a substantial amount of at least 10% campestanol has been found to effectively lower serum cholesterol levels when incorporated in edible commodities. Upon esterification the composition is especially useful in edible fats and oils and in fat-containing... Agent: Arent Fox PLLC

20070249575 - Vascular endothelial receptor specific inhibitors: The present application describes isoindoles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful inhibitors of VEGFR.... Agent: Feldmangale, P.A.

20070249576 - Cefdinir oral suspension: The present invention discloses a novel powder for oral suspension of cefdinir. Also disclosed are methods of preparing the suspension and methods of treatment using the suspension.... Agent: Steven F. Weinstock Abbott Laboratories

20070249577 - Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures: The present invention relates to methods for reducing the risk of infection due to surgical or invasive medical procedures. The present invention also relates to methods for preventing infection due to surgical or invasive medical procedures.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070249578 - New amidino derivatives and their use as thrombin inhibitors: e

20070249579 - Diketo-piperazine and piperidine derivatives as antiviral agents: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070249580 - Novel cyclic amino benzoic acid derivative: [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or —(CH2)n— (n represents 0, 1 or 2); X represents a hydrogen atom, halogen atom, lower... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070249581 - Abnormal cannabidiols as agents for lowering intraocular pressure: h

20070249583 - Hmg-coa reductase inhibitors:

20070249582 - Method of treating substance abuse with quetiapine: This invention relates to a method of treating Substance Use such as Substance Abuse or Substance Dependence and in particular to the use of quetiapine in treating such disorders.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070249584 - Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof: The invention relates to the preparation of substituted caprolactams, a method for the preparation thereof, compositions containing them and the use thereof as a medicament, particularly as anticancer agents.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070249585 - Triazolobenzodiazepines and their use as vasopressin antagonists: R1 and R2 independently represent C1-6 alkyl; and Ring A represents a phenyl ring or a pyridinyl ring; may be useful in the treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including... Agent: Pfizer Inc

20070249586 - Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity:

20070249587 - Aromatic-ring-fused pyrimidine derivative: There are provided novel pyrimidine derivatives which has been fused with an aromatic heterocycle selected from thiophene, thiazole and pyridine or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070249589 - Novel diazepan derivatives: wherein A, X, R3, R4, R5, R6, R8, R9, R10, R11, R12, R13, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070249588 - Nicotinic acetylcholine receptor ligands: Acetylcholine receptor ligands of formula (I), wherein D, Ar1, E and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070249590 - Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders: e

20070249591 - Biaryl amino acids and their use in dna binding oligomers: Compounds of formula (1): Z′-CO-A-B—NH-Z (I) wherein: Z is H or an amino protecting group; Z′ is OH, a protected or activated hydroxyl group or Cl; A is an optionally substituted C5-6 arylene group; and B is an optionally substituted C5-6 arylene group.... Agent: Michael Best & Friedrich LLP

20070249592 - Use of selected cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients: The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, and to the use of said active compounds... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070249593 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249594 - Benzothiazine and benzothiadiazine compounds: e

20070249595 - Novel enantiomeric pure beta agonists, manufacturing and use as a medicament thereof:

20070249596 - Abnormal cannabidiols as agents for lowering intraocular pressure:

20070249597 - Pyrazoloquinolones are potent parp inhibitors:

20070249598 - Derivatives of 8-substituted xanthines: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Heller Ehrman LLP

20070249600 - Chemical compounds: Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070249599 - Novel chemical compounds: This invention relates to the newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070249601 - Compounds and therapeutical use thereof: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070249603 - 3-arylsulfonyl-quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders: s

20070249604 - 3-monosubstituted tropane derivatives as nociceptin receptor ligands: R7 is H or alkyl; and m and n are each 0-6, provided that the sum of m and n is 0-6; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions thereof, and the use of said compounds in the treatment of cough, pain, anxiety, asthma, depression, alcohol abuse,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070249602 - Abnormal cannabidiols as agents for lowering intraocular pressure:

20070249605 - Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof: This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070249606 - Morpholinyl piperidine glycine transporter inhibitors: The present invention is directed to morpholinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.... Agent: Merck And Co., Inc

20070249607 - Nk-1 and serotonin transporter inhibitors: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070249608 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249609 - Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses: e

20070249610 - Process for the preparation of [(1r), 2s]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester:

20070249611 - Dipeptidyl peptidase inhibitors:

20070249614 - Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof:

20070249615 - Pyridine [3,4-b] pyrazinones:

20070249613 - Reduction of toxicity of multi-targeting antifolates: The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting anti-folate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumour action... Agent: Harness, Dickey & Pierce, P.L.C

20070249616 - Substituted 1-benzyl-4-substituted piperazine analogues: Such compounds may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are... Agent: Cantor Colburn, LLP

20070249612 - Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors: The invention relates to compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.... Agent: Pfizer Inc.

20070249617 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists: e

20070249618 - Novel piperidine derivatives as histamine h3 receptor ligands for treatment of depression: Compounds of formula (I) wherein Ar1 and Q are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the treatment of depression.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070249619 - Diarylmethyl piperazine derivatives, preparations thereof and uses thereof: Compounds of general formula: as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain, depression and anxiety.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070249622 - Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases: This invention relates to the use of nicotine receptor agonists or analogues or derivatives thereof for treating inflammatory pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary... Agent: Buchanan, Ingersoll & Rooney PC

20070249621 - Pharmacological treatment of parkinson's disease: The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease.... Agent: Medlen & Carroll, LLP

20070249620 - Urea derivative: [wherein R1 is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070249623 - 1-(indole-6-carbonyl-d-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazine d-tartrate: 1-(Indole-6-carbonyl-D-phenylglycinyl)-4-(1-methyl-piperidin-4-yl)piperazine D-tartrate forms a stable crystalline salt and is an inhibitor of the serine protease, Factor Xa, useful in the treatment of cardiovascular disorders.... Agent: Eli Lilly & Company

20070249624 - 4-squarylpiperazine derivatives as antiviral agents: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with 4-squarylpiperazine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070249625 - Il-8 receptor antagonists: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070249626 - Diaza heterocyclic amide compounds and their uses: i

20070249627 - Tubulin inhibitor and process for its preparation: The invention provides 6-chloro-5-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate which is a tubulin inhibitor useful in the treatment of cancer and processes of making said hemifumarate.... Agent: Wyeth Patent Law Group

20070249630 - Phenethanolamine derivatives for treatment of respiratory diseases: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070249628 - Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons: The present invention relates to a method for treating patients exposed to chemical or biological weapons comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cells degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more... Agent: Foley And Lardner LLP Suite 500

20070249629 - Viral polymerase inhibitors: e

20070249631 - Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds:

20070249632 - Pharmaceutical compositions and use thereof: The present invention relates to pharmaceutical compositions and dosage compositions of compounds, including injectable formulations for the parenteral delivery of such compounds into patients in need of such treatment. Also featured are methods of making and using the compositions, including methods for the treatment of neoplastic diseases.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070249633 - 1,2,4-triazolo[1,5a] pyrimidines and use thereof for controlling plant-pathogenic fungi: R3 and R4, R6 and R7, R8 and R9 and/or R10 and R11 together with the nitrogen atom to which they are attached form a four-, five- or six-membered saturated or partially unsaturated ring which may be substituted as defined in the description; and n is 0 or an integer... Agent: Birch Stewart Kolasch & Birch

20070249634 - Triazolopyrimidine compounds and use thereof for controlling harmful fungi: R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently of one another selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl and alkynyl, where the 4 last-mentioned radicals may be substituted as defined in the description; or R3 and R4, or R6 and R7, or R8... Agent: Birch Stewart Kolasch & Birch

20070249635 - Fungicidal mixtures based on a triazolopyrimidine derivative and a conazole: ,

20070249637 - Inhibitors of hepatitis c virus protease, and compositions and treatments using the same: The present invention provides compounds of formula (I), (II) or (IV), or pharmaceutically acceptable salts and solvates thereof, which are useful as inhibitors of the Hepatitis C virus (HCV) protease enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals, including humans. The present invention also... Agent: Pfizer Inc

20070249636 - Selected fused heterocyclics and uses thereof: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.... Agent: Astrazeneca R&d Boston

20070249638 - Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments: R1 is C1-C6 linear or branched alkyl or C1-C6 linear or branched alkenyl; R2 is hydrogen, C1-C6 linear or branched alkyl or C1-C6 linear or branched alkenyl, C6-C14 aryl or C6-C14 aryl(C1-C6) linear or branched alkyl or C6-C14 aryl(C1-C6) linear or branched alkenyl, with the aryl group optionally substituted by... Agent: Nixon & Vanderhye, PC

20070249639 - Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives: The invention relates to the use of 9H-purine-2,6-diamine compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising 9H-purine-2,6-diamine compounds, novel 9H-purine-2,6-diamine compounds, and a process for the preparation of the novel 9H-purine-2,6-diamine compounds.... Agent: Novartis Corporate Intellectual Property

20070249640 - Pharmaceutical compositions and use thereof: The present invention relates to pharmaceutical compositions and dosage compositions of compounds, including injectable formulations for the parenteral delivery of such compounds into patients in need of such treatment. Also featured are methods of making and using the compositions, including methods for the treatment of neoplastic diseases.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070249641 - Adenosine a3 receptor modulators: wherein R, R2, R3 and A have the meanings given in the specification, are endowed with selective A3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A3 receptor, or can be used in a diagnostic application... Agent: Christopher A Klein King Pharmaceuticals, Inc

20070249642 - Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione: e

20070249643 - Solid pharmaceutical dosage form: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable... Agent: Robert Deberardine Abbott Laboratories

20070249644 - Compounds and methods for the treatment of asthma: Compounds and methods for the treatment of asthma are disclosed. The methods involve mast cell stabilization together with selective inhibition of iNOS. The compounds are combinations of a mast cell inhibiting moiety and an inhibitor of iNOS. An example is:... Agent: Heslin Rothenberg Farley & Mesiti PC

20070249645 - Thiazole compounds useful as inhibitors of protein kinase: or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK3, Aurora2, and Syk mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein... Agent: Vertex Pharmaceuticals Inc.

20070249647 - Substituted cis- and trans-stilbenes as therapeutic agents: The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a... Agent: Coleman Sudol Sapone, P.C.

20070249646 - Use of tetrahydropyridines in the treatment of central nervous system disorders: Disclosed are methods for alleviating symptoms of neuropsychiatric disorders using tetrahydropyridine derivatives bearing aromatic substituents. The method comprises administering to an individual a tetrahydropyridine derivative bearing aromatic substituents in an amount effective to alleviate symptoms of the neuropsychiatric disorder.... Agent: Hodgson Russ LLP The Guaranty Building

20070249649 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249648 - Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases: The invention provides compounds of general formula. wherein A, B, W, X, Y, Z, D, E, R1 and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20070249651 - Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors: The present invention provides the combined use of acryloyl distamycin derivatives, in particular α-bromo- and -α-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and an antineoplastic topoisomerase I or II inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in... Agent: Nikaido, Marmelstein, Murray & Oram LLP Metropolitan Square

20070249650 - Methods for preparing dehydrocavidine, dehydroapocavidine or their composition, their use and medicinal compositon containing them: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then... Agent: Ruay L. Ho Ipfortune LLC

20070249652 - Phenanthridinium derivatives as dna binding agents: New classes of heterocyclic aromatic cationic compounds are disclosed, and in particular new classes of phenanthridinium derivatives, most notably dihydro-imidazo-phenanthridinium (DIP) compounds. These findings are based on the reaction of the middle b ring of a phenanthridinium core with primary amines to form DIP compounds (Formula A) or secondary amines... Agent: Dann, Dorfman, Herrell & Skillman

20070249653 - Tetracyclic benzamide derivatives and methods of use thereof: The invention relates to Tetracyclic Benzamide Derivatives; compositions comprising a Tetracyclic Benzamide Derivative; and methods for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer, comprising administering to a subject in need thereof an effective amount... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070249654 - Method for controlled polymerization of o-carboxy anhydrides derived from alpha-hydroxy acids: The invention concerns a method for preparing poly(-hydroxy acids), the polymerization reaction being performed in controlled manner in the presence of a catalytic system including a base, said base being a 5- or 6-membered aromatic heterocycle comprising at least one endocyclic nitrogen atom, provided that when the base is used... Agent: Foley And Lardner LLP Suite 500

20070249655 - 4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones: the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters or metabolites thereof, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(═O), C(═O)OH, C1-4alkyloxyC(═O), C1-4alkylC(═O), mono- or di(C1-4alkyl)aminoC(═O), arylaminoC(═O), N-(aryl)-N-(C1-4alkyl)aminoC(═O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; R2 is H, C1-4alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl,... Agent: Philip S. Johnson Johnson & Johnson

20070249656 - Hfa suspension formulations containing an anticholinergic: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl -3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070249657 - 1-aza-bicyclo3.3.1nonanes: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein... Agent: Novartis Corporate Intellectual Property

20070249659 - Imidazopyridine compound: wherein R1 and R2 each independently represent a C1-6 alkyl group et al; R3 and R4 each independently represent a hydrogen atom, a methyl et al; Ar1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar2 represents an aromatic... Agent: Merck And Co., Inc

20070249658 - Pyrrolo[3,2-c]pyridine deriatives and processes for the preparation thereof: The present invention provides novel pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump... Agent: Sughrue Mion, PLLC

20070249660 - Pharmacologically acceptable salts of clopidogrel: The invention relates to polymorphous forms of (+)-(S)-clopidogrel hydrogen bromide, described as polymorphous “form A”, polymorphous “form B”, polymorphous “form C”, polymorphous “form D”, polymorphous “form E”, and polymorphous “form F”, in addition to polymorphous forms of (+)-(S)-clopidogrel napsylate, that are described as polymorphous “form A” and polymorphous “form B”... Agent: Hoffmann & Baron, LLP

20070249662 - Process for the preparation of pyridine compounds: e

20070249661 - Compounds for inflammation and immune-related uses:

20070249663 - Pyrazolo[1,5-a]pyridines and medicines containing the same: [wherein R1 represents methoxy, ethyl, methylthio, etc., R2, R3 and R4 each represent hydrogen, a halogen, etc., R5 and R6 each represent —X5—X6—X7 (wherein X5 represents a single bond or —CO—, X6 represents a single bond, —NR3a, etc. and X7 and R3a each represent hydrogen, C1-10 alkyl, etc.), and Ar... Agent: Birch Stewart Kolasch & Birch

20070249664 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070249665 - 1-aryl-4-substituted isoquinolines: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to... Agent: Edwards Angell Palmer & Dodge LLP

20070249666 - P2x7 antagonists to treat affective disorders: The present invention provides methods to treat mood disorders and anxiety disorders using antagonists of the P2X7 receptor and pharmaceutical compositions thereof, or combinations.... Agent: Robert Deberardine Abbott Laboratories

20070249667 - Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases: the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the above compounds and one or more other... Agent: Philip S. Johnson Johnson & Johnson

20070249668 - Control of atp release by red blood cells and therapeutic applications thereof: The invention is based upon the discovery that red blood cells contain phosphodiesterase 3B (PDE3B), and that inhibition of that phosphodiesterase allows for an enhanced accumulation of cAMP and subsequent release of ATP. It was further discovered that RBCs treated with insulin accumulate significantly less cAMP and release significantly less... Agent: Saint Louis University Office Of Innovation And Intellectual Property

20070249669 - Crystalline 2-amino-3-cyanoquinoline derivatives, process of their preparation and pharmaceutical compositions containing them: The invention relates to the crystalline and amorphous forms of the desmotrope of general formula IB and its salts and solvates, and their preparation.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070249670 - Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof: The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia, including myocardial ischemia, and processes for making the compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070249671 - Pharmaceutical composition for piperidinoalkanol compounds: The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070249674 - Crystalline forms of a dimethylphenyl compound: The invention relates to crystalline free base forms of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also relates to pharmaceutical compositions containing or prepared from such crystalline forms; processes and intermediates useful for preparing such crystalline forms; and methods of using such crystalline forms to, for example,... Agent: Theravance, Inc.

20070249675 - Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary... Agent: Theravance, Inc.

20070249672 - Il-8 receptor antagonists: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070249673 - Method for administering tolperisone: The present invention is directed to methods of administering tolperisone (2,4′-dimethyl-3-piperidinopropiophenone; 1-propanone, 2-methyl-1-(4-methylphenyl)-3-(-piperidinyl)), and kits comprising the same.... Agent: Robins & Pasternak LLP

20070249676 - Cyanoguanidine prodrugs: e

20070249677 - Treatment of osteoarthritis and dosing regimen for arzoxifene: The present invention provides a method for treating osteoarthritis in a mammal, comprising administering to a mammal in need thereof, an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof.... Agent: Eli Lilly & Company

20070249680 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249679 - Imidazol-2-one compounds useful in the treatment of various disorders: e

20070249678 - Synthesis and uses of pyroglutamic acid derivatives: Novel pyroglutamic acid derivatives (I), wherein R1 is −OH, −ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing... Agent: Moore & Van Allen PLLC

20070249681 - Bupivacaines: The present invention describes a new method for the separation of bupivacaine enantiomers consisting in a continuous separation process performed without heating, by the selective precipitation of their diastereomeric salts with tartaric acid. This heatless process avoids the degradation of the reagents granting a continuous process feature to the procedure.... Agent: Birch Stewart Kolasch & Birch

20070249683 - Dicarboxamide derivatives: e

20070249682 - Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications: The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070249684 - Solid forms of the magnesium salt of s-omeprazole and processes for their preparation: New solid forms of the active ingredient magnesium salt of S-omeprazole, obtainable by a preparation process including: a) crystallizing a magnesium salt of S-omeprazole from a solution of a magnesium salt of S-omeprazole in a solvent system that includes a mixture of methanol/water with an amount of water equal to... Agent: Berenbaum, Weinshienk & Eason, P.c

20070249685 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249686 - Modulators of crth-2 receptor activity for the treatment of prostaglandin d2 mediated diseases: The invention relates to substituted acids as useful pharmaceutical compounds for treating respiratory disorders as asthma, pharmaceutical compositions containing them, and processes for their preparation.... Agent: Fish & Richardson P.C.

20070249687 - Carbamoylpyridone derivatives having inhibitory activity against hiv integrase: R3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted amino, optionally substituted lower alkylamino, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclic group, or optionally substituted heterocyclic lower alkyl) or a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070249688 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using... Agent: Eli Lilly & Company

20070249689 - Pre-mixed, ready-to-use pharmaceutical compositions: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20070249690 - N-[2-(4-pyridinyl)ethyl]benzamide derivatives as fungicides: o

20070249691 - Mercaptoimidazoles as ccr2 receptor antagonists: a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine, a polymorphic form or a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxyC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl or heteroaryl; each R2 independently represents halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono- or di(C1-4alkyl)amino, nitro, aryl or aryloxy;... Agent: Philip S. Johnson Johnson & Johnson

20070249692 - Inhibitors of crystallization in a solid dispersion: A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may... Agent: Steven F. Weinstock Abbott Laboratories

20070249693 - Total synthesis of salinosporamide a and analogs thereof: The present invention relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein... Agent: Knobbe Martens Olson & Bear LLP

20070249694 - Metaxalone formulations and methods for the preparation thereof: The invention provides pharmaceutical metaxalone compositions having improved bioavailability, food effect, and/or relative food effect, as well as methods of making such metaxalone compositions.... Agent: Kenyon & Kenyon LLP

20070249695 - Preventive and/or therapeutic agents for meniere's disease: The present invention relates to preventive and/or therapeutic agents for Meniere's disease, which comprise a leukotriene antagonist (such as pranlukast hydrate) as an active ingredient. Leukotriene antagonists (such as pranlukast hydrate) are effective in ameliorating various symptoms, such as hearing impairment, tinnitus, a feeling of fullness in the ear and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070249696 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20070249698 - Cck-1 receptor modulators: Certain imidazole compounds are CCK1 modulators useful in the treatment of CCK1 mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20070249697 - Novel imidazolidine derivatives: A is cyano or the like; B is hydrogen, halogen, or the like; X1 and X2 are each independently selected from O and S; E is a C1-4 alkyl group; and R1, R2, R3 and R4 are each independently selected from a hydrogen atom and a C1-C6 alkyl group, and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070249699 - Pesticide compositions and methods for their use: This invention relates to agricultural compositions, particularly pesticidal compositions which find particular use as a fungicide or herbicide composition. The pesticidal composition can include one or more fatty acids and one or more organic acids different from the fatty acid. The organic acid can but need not exhibit any fungicidal... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070249700 - Pyrazolone compounds useful for treatment of cerebrovascular disorders associated with ischemic stroke: i

20070249701 - Cyclic amine ccr5 receptor antagonists: Remedies or prophylactics for diseases in association with CCR5 such as AIDS, rheumatoid arthritis or nephritis comprising a cyclic amine compound represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, as an active ingredient.... Agent: Sughrue Mion, PLLC

20070249702 - Calcilytic compounds: The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.... Agent: Nps Pharmaceuticals, Inc.

20070249703 - (hydroxyphenyl)-1h-indole-3-carbaldehyde oxime derivatives as estrogenic agents: e

20070249704 - Process for the preparation of fluvastatin sodium salt: The present invention is directed to a process for preparing Fluvastatin Sodium salt by basic hydrolysis of its alkyl ester. The reaction is performed in conditions suitable to allow a selective hydrolysis of the desired syn isomer, while the unwanted anti isomer is removed by extraction, thus reducing its content... Agent: Dickstein Shapiro LLP

20070249705 - N-(1-(2,3-dihydro-1h-inden-5yl)-2-oxo-3-pyrrolidinyl)-sulfonamide derivatives for use as factor xa inhibitors: and pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compound(s) of formula (I), pharmaceutical compositions containing compound(s) of formula (I) and to the use of compound(s) of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070249706 - Use of certain biphenyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms): d

20070249708 - C7 ester and c10 hydroxy substituted taxanes: Taxanes having an ester substituent at C(7), a hydroxy substituent at C(10), and a range of C(2), C(9), C(14), and side chain substituents.... Agent: Senniger Powers

20070249707 - Taxanes having c7 hydroxy and c10 heterosubstituted acetate substituents: Taxanes having a heterosubstituted acetate substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.... Agent: Senniger Powers

20070249709 - Crystal forms of (s)-(8(2,6-dichlorophenyl)-6-fluoro-2,3-dihydro benzo[b][1,4]dioxin-2-yl)methanamine hydrochloride salt: The present invention is directed to crystal forms of the 5-HT2C agonist (S)-(8-(2,6-dichlorophenyl)-6-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanamine hydrochloride, as well as compositions, processes of preparation, and uses thereof.... Agent: Fish & Richardson P.C.

20070249710 - Biaromatic compounds and cosmetic/pharmaceutical applications thereof: e

20070249712 - Peracetic teat dip: A teat dip formula is disclosed for use on dairy animals with the objective of reducing or preventing mastitis. The teat dip formula preferably includes up to about 2% of peracetic acid in solution made by mixing acetic acid, hydrogen peroxide, and from up to about 5% by weight of... Agent: Smith Law Office

20070249711 - Triterpene compounds which are effective on improvement of brain function: The present invention relates to the triterpene compounds improving in brain functions. In particular, the present invention relates to a novel use of the triterpene compounds represented by the Formula 1 for improving decreased memory and a pharmaceutical composition for improving brain functions comprising the triterpene compounds represented by the... Agent: Ronald R Santucci Frommer Lawrence & Haug

20070249714 - Method of treating skin requiring fractional resurfacing treatment: A treatment regimen for treating skin subject to fractional resurfacing procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070249713 - Prevention of retinopathy by inhibition of the visual cycle: The invention relates to compounds capable of inhibiting the visual cycle and/or dark adaptation and their use for treatment and prevention of non-degenerative retinal diseases with specific emphasis on the prevention and treatment of diabetic retinopathy, retinopathy of prematurity, branch retinal vein occlusion, central retinal vein occlusion, open-angle glaucoma, veovascular... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070249716 - Illuminator for photodynamic therapy: An apparatus and method for photodynamic therapy or photodynamic diagnosis using an illuminator comprising a plurality of light sources generally conforming to a contoured surface and irradiating the contoured surface with substantially uniform intensity visible light. The light sources may comprise generally U-shaped fluorescent tubes that are driven by electronic... Agent: Foley And Lardner LLP Suite 500

20070249717 - Preventive/therapeutic agent for visceral pain: The present invention provides an agent for the prophylaxis or treatment of visceral pain associated with gastrointestinal tract diseases, which contains lysine. Using the prophylactic or therapeutic agent, gastrointestinal tract diseases accompanying visceral pain, such as intestinal disorder, irritable bowel syndrome, functional dyspepsia, gastro esophageal disease, functional abdominal pain syndrome,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070249718 - Stable gabapentin compositions: Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070249715 - Use of neboglamine (cr 2249) as an antipsychotic and neuroprotective: Use of neboglamine, (S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), of the racemate thereof or of a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of schizophrenia.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070249719 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20070249720 - Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability: The present invention relates to a pharmaceutical composition comprising a thiourea derivative or its pharmaceutically acceptable salt, a cyclodextrin or its derivative; and a pharmaceutical formulation comprising same.... Agent: Heslin Rothenberg Farley & Mesiti PC

20070249721 - Hair restorer: The object of the present invention is to provide a hair restorer which exhibits a stimulatory effect on hair restoration against hair loss, hair thinning, split ends, hair graying, etc., with higher stability and safety than those of known hair restorers containing 5-aminolevulinic acids as active components. By using 5-aminolevulinic... Agent: Morgan & Finnegan, L.L.P.

20070249723 - Methods for preparing sulfonamide compounds: e

20070249722 -